Navigation Links
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009

en aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours post-dose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13 hour post-dose efficacy data for pediatric patients included in its product labeling. - By July 24, 2009 VYVANSE had achieved a US ADHD market share of 12.3% based on weekly prescription volumes. ADDERALL XR - for the treatment of ADHD - On April 2, 2009 Teva announced that it had commenced commercial shipment of its authorized generic version of ADDERALL XR. In Q2 2009 sales of ADDERALL XR declined by 77% to $67 million. A decline in ADDERALL XR sales subsequent to generic launch was anticipated and was already reflected in our guidance framework.

Pipeline

INTUNIV(TM) - for the treatment of ADHD in children and adolescents in the US.

    - On May 19, 2009 Shire announced that a randomized placebo controlled
      trial had met its primary objective, evaluating the effects of INTUNIV
      on oppositional symptoms in children aged 6 to 12 years with a
      diagnosis of ADHD and the presence of oppositional symptoms.

    - The Prescription Drug User Fee Act date ("PDUFA") for INTUNIV was July
      27, 2009. Shire has received a Complete Response Letter from the FDA
      for INTUNIV. Shire and the FDA were not able to reach agreement on
      final product labeling in time to meet the PDUFA date. The FDA did not
      identify safety concerns regarding INTUNIV, request new clinical data or
      additional analyses in the Complete Response Letter. Shire and the FDA
      will continue to work together to resolve the remaining labeling
      language over the next 4-8 weeks and we anticipate launch in the fourth
      quarter of 2009 as planned.

    VYVANSE - for the treatment of non ADHD indications in adults

    - Shire is conducting Phase 2 pilot cli
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related biology technology :

1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... May 23, 2013 Graphite Metallizing ... self-lubricating bushings mounted in stainless steel pillow blocks. ... of GRAPHALLOY with the application and installation versatility ... Pillow Blocks work exceptionally well when submerged ... hostile liquids such as acids, alkalies, hydrocarbons, black ...
(Date:5/23/2013)... 23, 2013  Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season.   StemCyte, ... support awareness of umbilical cord blood banking and its ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... , , , ... CRGN ) today reported its financial results for the ... its outstanding convertible debt and reached an agreement in principle, expressed ... lawsuits filed in the State of Connecticut and the State of ...
... PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), ... biopharmaceutical, medical device and related industries, announced today results for the second ... all comparative numbers refer to changes from the same period a year ... of the second quarter of 2009 were: , , ...
... , , , ... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... 2009, the Company entered into definitive purchase agreements with certain ... including Cato Holding Company, which is the venture capital affiliate ...
Cached Biology Technology:CuraGen Reports Second Quarter 2009 Financial Results 2CuraGen Reports Second Quarter 2009 Financial Results 3CuraGen Reports Second Quarter 2009 Financial Results 4CuraGen Reports Second Quarter 2009 Financial Results 5CuraGen Reports Second Quarter 2009 Financial Results 6CuraGen Reports Second Quarter 2009 Financial Results 7CuraGen Reports Second Quarter 2009 Financial Results 8ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 2Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 3Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 4Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 5
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... -- By creating a unique system of blood vessels ... an implanted device, the longevity and function of these ... led by researchers in the University of Louisville/ Jewish ... early online on August 23, 2010 in the ...
... a single gene can cause several types of developmental ... With support from the National Institutes of Health, ... a new gene scanning technology that cuts the cost ... is going to change the way we approach single-gene ...
... Iowa State University researchers will use grants of ... molecules, test technology that can detect food contamination, design ... with potential to grow the state,s economy. The ... to award 10 competitive grants totaling $942,389 from Iowa ...
Cached Biology News:New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports 2Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3Iowa State awards grants to develop health, energy and research technologies 2Iowa State awards grants to develop health, energy and research technologies 3Iowa State awards grants to develop health, energy and research technologies 4
...
...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... developed using a protein engineering approach that introduced ... of wild-type DNase I. These changes markedly increase ... result is a versatile enzyme that has a ... to maintain at least 50% of peak activity ...
Biology Products: